Peripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean residence time and subsequent potency against primary murine breast tumors after IV administration

Pharmaceutical Research

Volumn 32, Issue 3, 2015, Pages 1028-1044

  Wakaskar, Rajesh R ^a   Bathena, Sai Praneeth R ^a   Tallapaka, Shailendra B ^a   Ambardekar, Vishakha V ^b   Gautam, Nagsen ^a   Thakare, Rhishikesh ^a   Simet, Samantha M ^c   Curran, Stephen M ^a   Singh, Rakesh K ^a,c   Dong, Yuxiang ^a   Vetro, Joseph A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

drug delivery; peripheral shell cross linking; pluronic F127; poloxamer 407; polymer nanocarriers; premature drug release; vascular disrupting agents

Indexed keywords

COMBRETASTATIN A4; ETHYLENEDIAMINE; POLOXAMER; ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; CROSS LINKING REAGENT; DRUG CARRIER; ETHYLENEDIAMINE DERIVATIVE; MICELLE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSS LINKING; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SOLUBILITY; FEMALE; HEMATOCRIT; HUMAN; HUMAN CELL; HYDRODYNAMICS; HYDROPHOBICITY; IC50; IN VITRO STUDY; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BREAST NEOPLASMS; CELL CULTURE; CHEMICAL PHENOMENA; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; EVALUATION STUDY; FEASIBILITY STUDY; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; MICELLE; PATHOLOGY; PHARMACEUTICS; PROCEDURES; SOLUBILITY; TUMOR CELL LINE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CROSS-LINKING REAGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; ETHYLENEDIAMINES; FEASIBILITY STUDIES; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICE; MICE, INBRED BALB C; MICELLES; POLOXAMER; SOLUBILITY; STILBENES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84923012085     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1515-z     Document Type: Article

References (47)

1. Allen LV, Popovich NG, Ansel HC. Parenterals. In. Ansel's pharmaceutical dosage forms and drug delivery systems. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011. p. 432-3.
2. Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315-499.
3. Teicher BA. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval: Humana Press; 1997.
4. Yalkowsky SH. Techniques of Solubilization of Drugs: Books on Demand; 1993.
5. Batrakova EV, Bronich TK, Vetro JA, Kabanov AV. Polymeric Micelles as Drug Carriers. In: Torchilin VP, (Ed). Nanoparticulates as Drug Carriers London: Imperial College Press; 2006. p. 57-93.
6. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release: Off J Control Release Soc. 2001;73(2-3):137-72.
7. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001;47(1):113-31.
8. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst. 2002;19(1):1-72.
9. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci. 2003;92(7):1343-55.
10. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347-60.
11. Bulmus V, Woodward M, Lin L, Murthy N, Stayton P, Hoffman A. A new pH-responsive and glutathione-reactive, endosomal membrane-disruptive polymeric carrier for intracellular delivery of biomolecular drugs. J Control Release. 2003;93(2):105-20.
12. Veronese FM, Morpurgo M. Bioconjugation in pharmaceutical chemistry. Farmaco. 1999;54(8):497-516.
13. D'Souza AJ, Topp EM. Release from polymeric prodrugs: linkages and their degradation. J Pharm Sci. 2004;93(8):1962-79.
14. Bae Y, Fukushima S, Harada A, Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Ed. 2003;42(38):4640-3. S4640/4641-S4640/4611.
15. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24(1):1-16.
16. Hurter PN, Hatton TA. Solubilization of polycyclic aromatic hydrocarbons by poly (ethylene oxide-propylene oxide) block copolymer micelles: effects of polymer structure. Langmuir. 1992;8(5):1291-9.
17. Nagarajan R, Ganesh K. Comparison of solubilization of hydrocarbons in (PEO-PPO) diblock versus (PEO-PPO-PEO) triblock copolymer micelles. J Colloid Interface Sci. 1996;184(2):489-99.
18. Xing L, Mattice WL. Strong solubilization of small molecules by triblock-copolymer micelles in selective solvents. Macromolecules. 1997;30(6):1711-7.
19. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387-92.
20. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer. 2004;90(11):2085-91.
21. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4):987-92.
22. Savic R, Eisenberg A, Maysinger D. Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell interactions. J Drug Target. 2006;14(6):343-55.
23. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004;91(10):1775-81.
24. van Cornelus FN. Covalently cross-linked amphiphilic block copolymer micelles. Soft Matter. 2011;7(7):3246-59.
25. Thurmond II KB, Kowalewski T, Wooley KL. Water-soluble knedel-like structures: the preparation of shell-cross-linked small particles. J Am Chem Soc. 1996;118(30):7239-40.
26. O'Reilly RK, Hawker CJ, Wooley KL. Cross-linked block copolymer micelles: functional nanostructures of great potential and versatility. Chem Soc Rev. 2006;35(11):1068-83.
27. Read ES, Armes SP. Recent advances in shell cross-linked micelles. Chem Commun (Cambridge, U K). 2007(29):3021-3035.
28. Li Y, Xiao K, Luo J, Xiao W, Lee JS, Gonik AM, et al. Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. Biomater. 2011;32(27):6633-45.
29. Lee S-Y, Kim S, Tyler JY, Park K, Cheng J-X. Blood-stable, tumor-adaptable disulfide bonded mPEG-(Cys)4-PDLLA micelles for chemotherapy. Biomater. 2013;34(2):552-61.
30. Koo AN, Min KH, Lee HJ, Lee SU, Kim K, Kwon IC, et al. Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links. Biomater. 2012;33(5):1489-99.
31. Kwon SH, Kim SY, Ha KW, Kang MJ, Huh JS, Im TJ, et al. Pharmaceutical evaluation of genistein-loaded pluronic micelles for oral delivery. Arch Pharm Res. 2007;30(9):1138-43.
32. Aliabadi HM, Brocks DR, Mahdipoor P, Lavasanifar A. A novel use of an in vitro method to predict the in vivo stability of block copolymer based nano-containers. J Control Release: Off J Control Release Soc. 2007;122(1):63-70.
33. Zhao D, Richer E, Antich PP, Mason RP. Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI. FASEB J. 2008;22(7):2445-51.
34. Ambardekar VV, Wakaskar RR, Sharma B, Bowman J, Vayaboury W, Singh RK, et al. The efficacy of nuclease-resistant Chol-siRNA in primary breast tumors following complexation with PLL-PEG(5K). Biomater. 2013;34(20):4839-48.
35. Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC. Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol. 2006;3(12):682-92.
36. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66(24):11520-39.
37. Giaever I, Keese CR. Monitoring fibroblast behavior in tissue culture with an applied electric field. Proc Natl Acad Sci U S A. 1984;81(12):3761-4.
38. Lundien MC, Mohammed KA, Nasreen N, Tepper RS, Hardwick JA, Sanders KL, et al. Induction of MCP-1 expression in airway epithelial cells: role of CCR2 receptor in airway epithelial injury. J Clin Immunol. 2002;22(3):144-52.
39. Zudaire E, Cuesta N, Murty V, Woodson K, Adams L, Gonzalez N, et al. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest. 2008;118(2):640-50.
40. Tiruppathi C, Malik AB, Del Vecchio PJ, Keese CR, Giaever I. Electrical method for detection of endothelial cell shape change in real time: assessment of endothelial barrier function. Proc Natl Acad Sci U S A. 1992;89(17):7919-23.
41. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer. 1999;81(8):1318-27.
42. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 2001;21(1A):93-102.
43. Hug TS. Biophysical methods for monitoring cell-substrate interactions in drug discovery. Assay Drug Dev Technol. 2003;1(3):479-88.
44. Ryu J, Jeong YI, Kim IS, Lee JH, Nah JW, Kim SH. Clonazepam release from core-shell type nanoparticles of poly(epsilon-caprolactone)/poly (ethylene glycol)/poly (epsilon-caprolactone) triblock copolymers. Int J Pharm. 2000;200(2):231-42.
45. Alexandridis P, Holzwarth JF, Hatton TA. Micellization of Poly (ethylene oxide)-Poly (propylene oxide)-Poly (ethylene oxide) Triblock Copolymers in Aqueous Solutions: Thermodynamics of Copolymer Association. Macromolecules. 1994;27(9):2414-25.
46. Chen H, Kim S, Li L, Wang S, Park K, Cheng JX. Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging. Proc Natl Acad Sci U S A. 2008;105(18):6596-601.
47. Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev. 1997;49(3):279-95.